Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarah Creamer (NPI 1659626927)

Field	Value
Entity Type	Individual
Organization	Sarah Creamer
Address	2620 W Faidley Ave
City	Grand Island
State	NE
ZIP	68803
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 23, 2012

Payer Source	Total Paid
Medicare	$696.2K
Medicaid	$0

Key Findings

This provider reports total Medicare revenue of $696.2K and has no Medicaid billing on file, so the public claims record shows an effectively single‑payer footprint concentrated in Medicare rather than a mixed Medicare/Medicaid practice. The absence of any Medicaid codes on file indicates payers and utilization analyses should treat this profile as Medicare‑centric when modeling volumes or contracting levers.

Revenue is highly concentrated in a small set of services: the precomputed top‑3 Medicare codes account for 84.3% of this provider's Medicare revenue, led by J9271 ($438.9K, 63.6%), followed by 99214 ($74.9K, 10.9%) and J0897 ($68K, 9.9%). This degree of concentration signals that a few high‑impact codes, particularly J9271, are the primary revenue drivers for the practice.

The taxonomy (Hematology & Oncology Physician) and the code mix strongly indicate an outpatient oncology infusion practice: J9271 (pembrolizumab) is the single largest revenue source and multiple chemotherapy administration codes appear in the top list (96413, 96365, 96417, 96411, 96415), reflecting routine IV immunotherapy and chemotherapy delivery alongside office visits. High counts for infusion and administration codes combined with frequent E/M encounters are consistent with longitudinal oncology care rather than a purely consultative service.

Competitive standing for the highest‑revenue drug: J9271 (10.2K claims, $438.9K revenue) ranks #1153 of 1841 nationally (37th percentile) and is labeled as typical/unremarkable volume, so this provider is a modest participant in national pembrolizumab billing rather than a dominant national center for that drug. Similarly, J0897 (3.8K claims, $68K revenue) ranks #3715 of 10057 (63th percentile) and is characterized as typical, indicating mid‑tier activity in denosumab relative to peers.

In contrast to the infusion drugs, the office visit code 99214 (842 claims, $74.9K revenue) ranks #17359 of 479517 providers nationally (96th percentile) and is labeled notably above typical national volume. This suggests stronger than average outpatient management volume per clinician for established visits, implying a sustained ambulatory follow‑up role in addition to infusion services.

Several high‑count codes generate very low revenue per claim, illustrating a mix of high‑frequency, low‑reimbursement items alongside high‑cost drugs: J1439 shows 16.5K claims but only $16.5K revenue ($1 avg paid/claim) and ranks #956 of 1209 (19th percentile, described as typical/unremarkable), while J2469 is 940 claims and $940 revenue. These line items appear to be routine adjuncts or supply reimbursements that contribute volume but not material revenue.

The provider’s NPI was enumerated on 2012-07-23 (~14 years ago), indicating an established practice tenure in the community. That length of enrollment supports interpretation of the observed patterns as a stable, ongoing oncology outpatient operation rather than a transient or newly entered provider.

Because 84.3% of Medicare revenue is concentrated in the precomputed top three codes and a single drug (J9271) represents 63.6% of total Medicare revenue, the practice’s overall revenue profile is highly sensitive to utilization and reimbursement changes for those specific codes. For payer strategy or network planning, shifts in access to pembrolizumab, changes in coding patterns for 99214, or modifications to denosumab coverage would materially affect this provider’s Medicare revenue base.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

29 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,210	$40	$438.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	840	$90	$74.9K
J0897	Injection, denosumab, 1 mg	3,780	$20	$68K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	280	$90	$26K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	160	$130	$19.7K
J1439	Injection, ferric carboxymaltose, 1 mg	16,500	$1	$16.5K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	70	$160	$10.6K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	650	$10	$5.2K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	190	$20	$3.9K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	90	$40	$3.9K

Showing 1–10 of 29

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Sarah Creamer — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

29 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	20	30	14,400	$40	$671.6K
J0897	51	200	2,040	$20	$62.7K
J1439	26	30	25,880	$1	$26.4K
96413	29	80	60	$90	$18.2K
99214	118	3,210	110	$70	$14.9K
99213	2,011	3,220	90	$50	$7.9K
99215	90	920	40	$110	$7K
99204	949	1,320	30	$100	$5.3K
96417	27	40	100	$50	$5K
99205	55	380	20	$140	$5K

Showing 1–10 of 29

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarah Creamer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Sarah Creamer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Go Physical Therapy, LLC	NE	Physical Therapist	$0	$12.4M
Saint Francis Medical Center	NE	General Acute Care Hospital	$0	$11M
Mid-plains Center For Behavioral Healthcare Services, Inc.	NE	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$10M
Grand Island Clinic Inc	NE	Family Medicine Physician	$0	$9.2M
Heartland Health Center, Inc.	NE	Federally Qualified Health Center (FQHC)	$0	$8.8M
Midwest Emergency Grand Island Inc	NE	Emergency Medicine Physician	$0	$3.8M
Active Family Chiropractic And Acupuncture PC	NE	Chiropractor	$0	$3.8M
Twin Rivers Urgent Care LLC	NE	Family Medicine Physician	$0	$2.9M
Family Practice Of Grand Island P C	NE	Family Medicine Physician	$0	$2.2M
Wholeness Healing Center PC	NE	Mental Health Counselor	$0	$2.1M

Sarah Creamer — Billing Profile & Reimbursement Data

Sign up for Sarah Creamer — Billing Profile & Reimbursement Data policy alerts

Sarah Creamer — Billing Profile & Reimbursement Data

Sign up for Sarah Creamer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References